Sensei Biotherapeutics (SNSE) Competitors $9.02 +0.02 (+0.24%) Closing price 03:58 PM EasternExtended Trading$8.75 -0.27 (-3.00%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SNSE vs. VRCA, BRNS, CALC, TELO, GRCE, ATHE, IPSC, MDCX, LTRN, and LVTXShould you be buying Sensei Biotherapeutics stock or one of its competitors? The main competitors of Sensei Biotherapeutics include Verrica Pharmaceuticals (VRCA), Barinthus Biotherapeutics (BRNS), CalciMedica (CALC), Telomir Pharmaceuticals (TELO), Grace Therapeutics (GRCE), Alterity Therapeutics (ATHE), Century Therapeutics (IPSC), Medicus Pharma (MDCX), Lantern Pharma (LTRN), and LAVA Therapeutics (LVTX). These companies are all part of the "pharmaceutical products" industry. Sensei Biotherapeutics vs. Its Competitors Verrica Pharmaceuticals Barinthus Biotherapeutics CalciMedica Telomir Pharmaceuticals Grace Therapeutics Alterity Therapeutics Century Therapeutics Medicus Pharma Lantern Pharma LAVA Therapeutics Verrica Pharmaceuticals (NASDAQ:VRCA) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Do analysts recommend VRCA or SNSE? Verrica Pharmaceuticals currently has a consensus target price of $80.00, suggesting a potential upside of 1,880.20%. Sensei Biotherapeutics has a consensus target price of $55.00, suggesting a potential upside of 509.62%. Given Verrica Pharmaceuticals' higher probable upside, research analysts clearly believe Verrica Pharmaceuticals is more favorable than Sensei Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verrica Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20Sensei Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has better earnings and valuation, VRCA or SNSE? Sensei Biotherapeutics has lower revenue, but higher earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerrica Pharmaceuticals$7.57M5.04-$76.58M-$8.28-0.49Sensei BiotherapeuticsN/AN/A-$30.16M-$21.31-0.42 Does the media refer more to VRCA or SNSE? In the previous week, Sensei Biotherapeutics' average media sentiment score of 1.00 beat Verrica Pharmaceuticals' score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Verrica Pharmaceuticals Neutral Sensei Biotherapeutics Positive Do insiders & institutionals have more ownership in VRCA or SNSE? 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 23.2% of Sensei Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, VRCA or SNSE? Verrica Pharmaceuticals has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Is VRCA or SNSE more profitable? Verrica Pharmaceuticals' return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Verrica PharmaceuticalsN/A N/A -115.48% Sensei Biotherapeutics N/A -72.13%-61.35% SummaryVerrica Pharmaceuticals and Sensei Biotherapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Sensei Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNSE vs. The Competition Export to ExcelMetricSensei BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.37M$3.14B$5.81B$10.36BDividend YieldN/A2.37%5.86%4.62%P/E Ratio-0.4221.3676.8726.99Price / SalesN/A248.62449.2288.69Price / CashN/A45.4837.2260.63Price / Book0.309.6913.836.37Net Income-$30.16M-$52.92M$3.29B$271.46M7 Day Performance-3.51%1.44%0.94%2.34%1 Month Performance9.09%6.02%5.31%7.77%1 Year Performance-7.12%12.89%84.25%31.08% Sensei Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNSESensei Biotherapeutics4.6339 of 5 stars$9.02+0.2%$55.00+509.6%-12.6%$11.37MN/A-0.4240Positive NewsShort Interest ↓Gap DownVRCAVerrica Pharmaceuticals3.0595 of 5 stars$4.94+4.0%$80.00+1,519.4%-75.1%$44.87M$14.70M-0.6040Gap UpHigh Trading VolumeBRNSBarinthus Biotherapeutics2.1164 of 5 stars$1.05-4.5%$3.00+185.7%-14.4%$44.79M$14.97M-0.61107Positive NewsCALCCalciMedica2.7236 of 5 stars$2.85-10.1%$16.00+461.4%-18.2%$44.29MN/A-1.7830Gap UpHigh Trading VolumeTELOTelomir Pharmaceuticals2.1019 of 5 stars$1.33-2.2%$15.00+1,027.8%-76.3%$43.90MN/A-2.461Negative NewsGRCEGrace Therapeutics2.8983 of 5 stars$3.07-2.5%$12.00+290.9%N/A$43.56MN/A-3.57N/ANews CoverageATHEAlterity Therapeutics2.011 of 5 stars$4.64-4.9%$12.00+158.6%+247.9%$43.27MN/A0.0010High Trading VolumeIPSCCentury Therapeutics1.8669 of 5 stars$0.50-0.7%$3.75+654.2%-70.4%$43.26M$6.59M-1.71170MDCXMedicus Pharma2.0969 of 5 stars$2.48+2.9%$23.50+847.6%N/A$42.94MN/A-1.85N/ANews CoverageAnalyst UpgradeGap UpLTRNLantern Pharma2.0619 of 5 stars$3.81-0.5%$25.00+556.2%+2.6%$41.36MN/A-2.1420LVTXLAVA Therapeutics1.6519 of 5 stars$1.54-0.3%$2.69+74.4%-14.8%$40.64M$11.98M-1.4760Negative NewsShort Interest ↑ Related Companies and Tools Related Companies VRCA Alternatives BRNS Alternatives CALC Alternatives TELO Alternatives GRCE Alternatives ATHE Alternatives IPSC Alternatives MDCX Alternatives LTRN Alternatives LVTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNSE) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sensei Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNSE Stock Alerts